A SINGLE-BLIND, RANDOMISED HOME-USE STUDY, IN 50 HEALTHY MALE AND FEMALE VOLUNTEERS, WITH SELF-ASSESSED ANXIETY, TO EVALUATE THE EFFICACY OF ONE NUTRITIONAL SUPPLEMENT COMPARED TO PLACEBO, AS MEASURED BY SELF-PERCEPTION QUESTIONNAIRE (SPQ).

Prepared for:

Nutreance 401 Riversville Road Greenwich CT. 06831 USA Prepared by:

PCR Corp. 8 Richmond Road Dukes Park Chelmsford Essex, CM2 6UA

Draft Report: 14th October 2016 Draft Report v2: 20th October 2016 Draft Report v3: 25th October 2016 Final Report: 26th October 2016 Final Report v2: 13th December 2016

Final v2 Page 1 of 30

A SINGLE-BLIND, RANDOMISED HOME-USE STUDY, IN 50 HEALTHY MALE AND FEMALE VOLUNTEERS, WITH SELF-ASSESSED ANXIETY, TO EVALUATE THE EFFICACY OF ONE NUTRITIONAL SUPPLEMENT COMPARED TO PLACEBO, AS MEASURED BY SELF-PERCEPTION QUESTIONNAIRE (SPQ).

PCR CORP REPORT NO: NUTUSE1M

I declare that the following report constitutes a true and faithful account of the procedures adopted and the results obtained in the performance of this study. The aspects of the study conducted by PCR Corp. were performed, where relevant, in accordance with the principles of Good Clinical Research Practice.

Barrie Drewitt (Principal Investigator)

Date 13th December 2016

Jo Broyd (Project Manager)

Date 13th December 2016

QUALITY ASSURANCE STATEMENT

This report has been audited and is considered to be an accurate description of the methods used and an accurate presentation of the data obtained during the conduct of the study.

Reece Statham (Quality Assurance Manager)

Date 13th December 2016

Final v2 Page 2 of 30

CONTENTS

1	SUMMARY	4
2	KEY STUDY PERSONNEL AND RESPONSIBILITIES	5
3	INTRODUCTION AND OBJECTIVES	6
4	STUDY DESIGN	6
5	SELECTION OF SUBJECTS	6
6	TEST ARTICLES.	7
7	STUDY PROCEDURE	
8	STUDY ETHICS	8
9	RESULTS	9
APP	PENDIX 1: SUBJECT CONSENT FORM	13
APP	PENDIX 2: SUBJECT INFORMATION SHEET - NUTUSE1M	16
	PENDIX 3: PRE-TREATMENT QUESTIONNAIRE	
	PENDIX 4: TEST ARTICLES INCI LISTINGS	
APP	PENDIX 5: RANDOMISATION	20
APP	PENDIX 6: SUBJECT DIARY	21
APP	PENDIX 7: SELF-PERCEPTION QUESTIONNAIRE	23
APP	PENDIX 8: SELF-PERCEPTION QUESTIONNAIRE INDIVIDUAL RESPONSES – TEST SUPPLEMENT	25
A DD	PENDLY OF SELE DEDCEDTION OUESTIONNAIDE INDIVIDUAL DI ACEDO	20

1 SUMMARY

Title: A single-blind, randomised home-use study, in 50 healthy male

and female volunteers, with self-assessed anxiety, to evaluate the efficacy of one nutritional supplement compared to placebo, as measured by Self-Perception Questionnaire (SPQ).

Study design: Single blind, randomized home-use study.

Test Articles: One active nutritional supplement and one placebo (Labelled):

Nutritional Supplement A
 Nutritional Supplement B

Number of subjects: Fifty (50)

Type of subjects: Healthy male and female volunteers, aged over 18 years, with

self-assessed anxiety.

Method: Subjects attended the test centre at baseline (Day 1) to

complete the informed consent form (ICF). Subjects were issued their supplement, diary and instructions. They were instructed on how to take their supplement, complete their diary over the next 30 Days, including the 2 Self-Perception Questionnaire (SPQ) questions daily, which are on their diary. At the end of the study (Day 30) subjects returned to the test centre to complete an

online Self-Perception Questionnaire (SPQ).

Conclusion: As can be seen from the data the product performed highly

favourably under Clearcast guidelines, over the 30 day testing period shown by Top 2 responses (Strongly Agree + Agree) being >80% (regarded as highly favourable). The Sponsor's product also performed statistically significantly better than the Placebo product for all comparable questions. With 100% of subjects noticing an improvement in their level of anxiety and 68% of

subjects feeling calmer after only 30 minutes.

Duration of study: Study Started: w/c 5th September 2016

Study Ended: w/e 7th October 2016

Location: PCR Corp.

8 Richmond Road

Dukes Park Chelmsford Essex CM2 6UA United Kingdom

Final v2 Page 4 of 30

2 KEY STUDY PERSONNEL AND RESPONSIBILITIES

Variable and a large and a lar	3 333
Key personnel	General responsibilities
Principal Investigator (PI) Barrie Drewitt	The Principal Investigator (DI) will be
PCR Corp	The Principal Investigator (PI) will be responsible for ensuring sufficient
Princeton Forrestal Center	resources are available to conduct the
307 College Road East	study according to Good Clinical
Princeton, NJ 08540	Practice (GCP), for the study design,
	compiling the results and writing the
Tel: 609-455-1112	clinical report.
Project Supervisor (PS)	
Andrew King	The Project Supervisor (PS) will be
PCR Corp	responsible for the conduct of the study
8 Richmond Road	on a daily basis.
Dukes Park	
Chelmsford	
Essex CM2 6UA	
United Kingdom	
Tel: +44 (0) 1245 934050	
Project Manager (PM)	
Jo Broyd	The Project Manager (PM) will be
PCR Corp	involved with the study design,
8 Richmond Road	compiling the results and writing the
Dukes Park	clinical report.
Chelmsford	
Essex CM2 6UA	
United Kingdom	
Tel: +44 (0) 1245 934050	
Project Co-ordinator (PC)	
Dan Watters	The Project Co-ordinator (PC) will be the
Nutreance	primary point of contact on behalf of the
401 Riversville Road	Sponsor of this project and will represent
Greenwich	the Sponsor (Nutreance) of this study.
CT. 06831	
Tel: 1 (800) 749-7776	
Email: support@nutreance.com	

Final v2 Page 5 of 30

3 Introduction and Objectives

The objective of this study was to evaluate the perceived efficacy of a nutritional supplement versus a placebo following continued home-use for four weeks via completion of a self-perception questionnaire (SPQ) at the end of the study. With the aim of supporting the following targeted claims proposed by sponsor:

X% of subjects noticed an improvement in their level of anxiety

X% of subjects felt calmer after only 30 minutes

Please note that it was the responsibility of the sponsor to determine the testing and study designs required for submission to entities such as the Home Shopping Network, QVC, etc.

4 STUDY DESIGN

Single-blind, randomised home-use study.

5 SELECTION OF SUBJECTS

5.1 Screening

A sufficient number of subjects were screened into the study to allow for fifty subjects to enter the active phase. Subjects satisfied the following inclusion and exclusion criteria, and the subjects accepted the prohibitions and restrictions and gave written informed consent (Appendix 1 & 2).

The suitability of potential subjects was confirmed before their acceptance onto the study by review of a study specific pre-treatment questionnaire (Appendix 3).

5.2 <u>Inclusion criteria</u>

- a) Healthy male and female volunteers, aged over 18 years of age, with self-assessed anxiety.
- **b)** Subjects have completed a written informed consent.

5.3 Exclusion criteria

- a) Subject is currently on prescription anti-anxiety medication or anti-depressants.
- **b)** Subject is pregnant, nursing, or planning to become pregnant;
- A current skin disease of any type (e.g. eczema, psoriasis) apart from mild facial acne.
- **d)** History of malignant disease.
- e) Significant past medical history of hepatic, renal, cardiac, pulmonary, digestive, haematological, neurological, locomotor or psychiatric disease.
- f) History of asthma requiring regular medication.
- **g)** Known sensitivity to the test article, similar materials or their constituents.
- **h)** Current participation in a clinical trial or follow-up.

Final v2 Page 6 of 30

5.4 Prohibitions and Requirements

- a) Subjects agree to use the trial product assigned as instructed, instead of their usual brand for the duration of the study.
- b) Subjects who are vegetarian and vegan to be made aware of the gelatin content in the pacebo capsule.

6 TEST ARTICLES

To the best of the Sponsor's knowledge and based on the information available, PCR Corp considered the test article to be safe for use in man.

The following test article was supplied by the Sponsor labelled as follows:

- 1. Supplement A
- 2. Supplement B

The test articles and placebo were decanted into plain packaging plastic bags by PCR Corp. The Sponsor has provided ingredient listings for the test article (see Appendix 4).

It was the responsibility of the Sponsor to determine, for each batch of the test article, the identity, strength, purity, composition and other characteristics which appropriately define the test article, before its use in the study. The determination of its stability and documentation of methods of synthesis or derivation were also the Sponsor's responsibility.

It was the responsibility of the Sponsor that the test article meets all necessary transport regulations, particularly those regulations involving the carriage of hazardous goods and the import/export of goods or equipment, and that any costs including tax/duty were fully met by the Sponsor prior to receipt of the test article at PCR Corp. No liability with regard to safe receipt or costs involved in the carriage of goods or equipment to any PCR Corp site was accepted.

On study completion any remaining unused test articles were disposed of, unless otherwise requested by the Sponsor, after issuance of the final report or 28 days after study completion, whichever came first. Sponsors requesting the return of products were liable for any costs incurred.

7 STUDY PROCEDURE

a) Study Outline

Subjects attended the test centre at baseline (Day 1) to complete the informed consent form (ICF). Subjects were issued with the test product (according to Randomisation; Appendix 5), diary (Appendix 6) and instructions for how to use the product at home for the next 4 weeks. Subjects completed 2 Self-Perception Questionnaire (SPQ) questions daily, which were on their diary card. At the end of the study (Day 30) subjects returned to the test centre to complete an online Self-Perception Questionnaire (SPQ).

b) Test Article Use

The test articles were used at home throughout the duration of the study. According to the usage instructions (Appendix 2).

Final v2 Page 7 of 30

c) Self-Perception Questionnaire (SPQ)

At the end of the study subjects completed an online SPQ (Appendix 7) on how the test product improved their anxiety.

8 STUDY ETHICS

8.1 <u>Declaration of Helsinki</u>

The study conformed to the requirements of the 1964 Declaration of Helsinki and its subsequent amendments (World Medical Association; 2013).

8.2 Subject consent

Subjects were informed of the nature, purpose and known risk of the study both orally and in writing and gave their written informed consent to participate in the study prior to any study procedures being performed (Appendix 1). Subjects were advised that they were free to withdraw from the study at any time without being obliged to give a reason. They were compensated for their time.

8.3 **Indemnity Provision**

The Sponsor was responsible, without regard to legal liability, and indemnified PCR Corp or any of their respective officers or employees in the event of claims for compensation from subjects suffering injury or other deterioration in health or well-being as a result of participation in this study, except and insofar as such claims arise as a result of any negligent act or omission on the part of PCR Corp employees or any persons undertaking or involved in the study by arrangement with PCR Corp.

Final v2 Page 8 of 30

9 RESULTS

9.1 Location and dates of the study

The study was performed at PCR Corp, between 5th September 2016 and 4th October 2016.

9.2 Subjects

Fifty (50) male and female subjects were enrolled onto the study and fifty (50) subjects completed the study.

9.3 Adverse events, adverse reactions and subjects not completing the study

No Adverse Events were reported.

9.4 Conclusions


As can be seen from the data the product performed highly favourably under Clearcast guidelines, over the 30 day testing period shown by Top 2 responses (Strongly Agree + Agree) being >80% (regarded as highly favourable). The Sponsor's product also performed statistically significantly better than the Placebo product for all comparable questions. With 100% of subjects noticing an improvement in their level of anxiety and 68% of subjects felt calmer after only 30 minutes.

Bar Graphs over page show the percentage of subjects that gave the top two responses (Strongly Agrees + Agrees) for the Active Supplement.

Final v2 Page 9 of 30


PCR CORP REPORT: NUTUSE1M

13th December 2016



Final v2 Page **10** of **30**

PCR CORP REPORT: NUTUSE1M



Final v2 Page 11 of 30

Table 1: Summary of % Responses for the Product Tested

Question Question	Strongly	Agree	Neither	Disagree	Strongly
4.00	Agree	()	Agree nor Disagree	Disagree	Disagree
After taking this product I noticed an improvement in my level of anxiety.	28	72	0	0	0
After taking this product I felt calmer after only 30 minutes.	8	60	28	4	0
After taking this product I felt calmer.	28	68	4	0	0
After taking this product I was able to sleep better.	8	88	4	0	0
After taking this product I felt more relaxed.	28	68	4	0	0
After taking this product I felt less worried.	12	68	20	0	0
After taking this product I felt I had better concentration	24	76	0	0	0
After taking this product, my breathing was more relaxed	16	68	12	4	0
After taking this product I had a more restful sleep	12	80	8	0	0
After taking this product I felt I had more energy	32	64	4	0	0
After taking the product I felt more alert during the day	24	76	0	0	0
After taking the product I felt I was able to face my normal anxiety triggers	8	76	12	4	0
After taking the product I felt more at ease with my daily routine	24	76	0	0	0
After taking the product I felt less irritable	28	68	4	0	0
The supplement was easy to include in my daily routine	48	52	0	0	0
The supplement was easy to swallow	36	64	0	0	0
I would recommend this product to a friend or family member.	56	44	0	0	0

<u>Table 2: Statistical Analysis – Paired TTest of Treatment vs Placebo</u>

Question N	lo.	1		2			3		4		!	5	6			7		8
A vs B		1.28E	E-03	2.52	E-02	1.74	4E-04	1.1	.0E-	04	1.07	'E-03	1.19	E-03	9.7	3E-04	2.21	LE-04
Question No.	9)	10		11	1	.2	13		1	4	15		16	17	18	19	20
A vs B	2.00	E-04 2	2.41E-	03 5.5	8E-05	9.73	E-04	2.64E	-04	1.22	E-04	3.17E-	02 2.0	0E-02	N/A	1.76E	-04 N/	A N/A

P<0.05 shows that the subject's perception of treatment product was statistically significantly better than the subject's perception of the placebo product.

Final v2 Page **12** of **30**

APPENDIX 1: SUBJECT CONSENT FORM

Study Coc	<u>de:</u>	<u> NUI</u>	<u>USE I</u>	Μ
Subject #:			_	

INTRODUCTION

You are being asked for your consent to participate in a research study. Prior to giving your consent, it is important that you take the time to read and understand what participation will involve. This consent form may contain technical language which you may not understand. If you do not understand any of this consent form, please ask the clinical staff any questions you may have.

You will be provided with a signed copy of this consent form and any other necessary written information prior to the start of the study.

OBJECTIVE

The objective of this research study is to determine the efficacy of one test article at reducing anxiety.

TEST ARTICLES

The test article is a nutritional supplement. The test article used will be through normal everyday use following usage instructions provided.

STUDY PROCEDURES

You will be one of approximately 50 subjects enrolled onto this study. Your participation in this study will last approximately four weeks (30 Days) and will include two visits to the testing facility.

Visit 1 (Study day 1 – approximately 30 minutes): Prior to acceptance on the study, you will be screened for eligibility to participate on the study and on confirmed eligibility consented to participate. Following verification of your acceptance and your written consent, you will be issued with the test product (with usage instructions and diary) to use at home for the next four weeks. You will need to answer the 2 questions of your diary card every day.

Visits 2 (Study day 30 – approximately 15 minutes): You will attend the study centre to complete an online questionnaire, return any unused test product and receive compensation.

RISKS

To the best of our knowledge, these products are not expected to induce an allergic reaction. While the potential for irritation or other reactions during this study are minimal, it is possible for a reaction to occur. Expected reactions for these test articles categories are mild in nature and may include the following: redness, itching, peeling or blistering. In addition to the risks described, there may be other risks that are currently unforeseeable.

No significant adverse reactions are expected to occur. However, if you develop an adverse reaction or complication as a result of your participation in this study, medical treatment will be provided by clinical staff nurses at PCR CORP or you will be referred for appropriate treatment at no cost to you, as long as you have followed the study instructions. Provisions of such medical care is not an admission of legal responsibility. You will be followed by PCR CORP until the adverse reaction has resolved. No additional compensation will be available to you. Neither the sponsoring company nor the investigating company will be held responsible for any future medical expenses.

Final v2 Page **13** of **30**

APPENDIX 1 - CONTINUED

BENEFITS

While it is likely that you will not receive any direct benefit from your participation in the study, the study results may have the potential to increase scientific knowledge about nutritional supplements and may allow for new and improved products to be marketed.

CONFIDENTIALITY

Information concerning you that is obtained in connection with this study will be kept confidential by PCR CORP, except that the sponsoring company whose product is being tested will receive a copy of the study records. The records will be uniquely coded to protect your and your child's identity. In addition, third party regulatory authorities, including the U.S. Food and Drug Administration (FDA), may inspect the records of the study. In all cases, your confidentiality will be maintained and your identity will remain private.

Your signature on the Informed Consent provides your permission for these agencies to view your personal information and the study data.

NEW FINDINGS

Any new information that is discovered during the study and which may influence your willingness to continue in the study will be made available to you.

MEDICAL TREATMENT

In the event of an emergency, dial 999. If you receive any medical care during the course of the study, inform medical personnel that your participating in a research study. Please contact PCR CORP staff as soon as possible to inform them of your condition.

WHO TO CONTACT

If you have any questions about this study or in the case of an emergency, contact **Andy King** on **01245 934050** during normal business hours.

VOLUNTARY PARTICIPATION/WITHDRAWAL

Your participation in this research study is strictly voluntary. You may refuse to participate or may discontinue participation at any time during the study without penalty or loss of benefits to which you are otherwise entitled. However, you must contact the test facility and inform a clinical staff member of your decision to withdraw from the study.

If you agree to participate in the study, you are also agreeing to provide PCR CORP with accurate information and to follow study instructions as given to you. If you fail to follow study instructions, you may be asked to discontinue participation.

Your participation in the study may be discontinued at any time without your consent by PCR CORP, regulatory agencies, or the sponsoring company for reasons of but not limited to a severe side effect and accompanying illness, or if you do not follow study instructions.

COMPENSATION

If you agree to your participation in this study, you will be paid £XX upon completion of the study.

Final v2 Page **14** of **30**

APPENDIX 1 – CONTINUED

NON-DISCLOSURE

As a condition to your participation in the study you are asked not to discuss any information regarding the products that you are testing, your experiences with the products, or your opinion of the products, nor share the products that you are testing with anyone outside of the testing facility. By your signature on the Consent you are agreeing to abide by this condition of participation.

CONSENT TO PARTICIPATE

I know that my participation in this study is voluntary and that I have the right to refuse to participate. I know that I may withdraw from the study at any time without penalty or loss of benefits to which I am otherwise entitled. If, at the discretion of the Investigator, it is best to discontinue my participation for reasons other than a failure to obey the directions of the study, I will be paid in full or for the portion of the study we have completed once the study is over.

CONSENT

I have read all of the pages of this consent form and have been given an opportunity to ask questions about this study. Answers to such questions (if any) were satisfactory. I am at least eighteen years old and without reservation give my consent to serve as a subject in this study. By signing this form, I have not given up any of my legal rights as a research subject. I will receive a copy of this signed consent document.

You are making a decision whether or not to participate. Your signature indicates that you have decided to participate, having read the information provided above.

Subject's Name Printed: First	Middle Initial	Last
Subject's Signature		Date
Signature of Person Conducting Co	onsent Discussion	Date
Subject Number		

Final v2 Page **15** of **30**

APPENDIX 2: SUBJECT INFORMATION SHEET - NUTUSE1M

Study Code: NUTUSE1M

You have agreed to your participation in a research study. By agreeing to participate, you are also agreeing to the following prohibitions and restrictions:

• Subjects agree to use the trial product assigned as instructed, instead of their usual brand for the duration of the study.

The study schedule is as follows:

Monday	Tuesday – Sunday (Week 1)							
5 th Sept	6th – 11th Sept							
Visit 1 – Use product at home, as instructed.								
Completion of informed consent. Answer 2 questions on diary card.								
Issue products, instructions and diary								
	Monday – Sunday (Week 2)							
	12 th – 18 th Sept							
	Use product at home, as instructed.							
	Answer 2 questions on diary card.							
	Monday – Sunday (Week 3)							
	19 th – 25 th Sept							
	Use product at home, as instructed.							
	Answer 2 questions on diary card.							
	Monday – Monday (Week 4)							
	26th - 3rd Oct							
	Use product at home, as instructed.							
	Answer 2 questions on diary card.							
Tuesday								
4 th Oct								
Visit 2 –								
Study End SPQ Co								
Product Ret								
Compensat	ion							

Please follow the usage instructions below:

Directions: Take 2 capsules in the morning, per day for 30 days which can be taken with or without food. Please DO NOT open the capsules.

*You must come in for all visits; no misses will be allowed. If you are unable to come in for a visit, your participation will be discontinued. Upon completion of this study on 4th October 2016, you will receive £XX for your participation.

If you have any questions about this study or in the case of a suspected allergic reaction, call Andy King on 01245 934050 during normal business hours.

Final v2 Page **16** of **30**

APPENDIX 3: PRE-TREATMENT QUESTIONNAIRE

FOR OFFICE USE ONLY							
SUBJECT'S INITIALS							
MALE/FEMALE							
AGE							
SUBJECT							
NUMBER							

Study Code: NUTUSE1M

STRICTLY CONFIDENTIAL

No	Yes	lusion Criteria	Inc
		Healthy male and female volunteers, aged over 18 years, with self-assessed anxiety.	1.
		Subject has completed a written informed consent.	2.
No	Yes	clusion Criteria	Exc
		Subject is pregnant, nursing, or planning to become pregnant	1.
		A current skin disease of any type at the test site (e.g. eczema, psoriasis)	2.
		History of malignant disease	3.
0		Significant past medical history of hepatic, renal, cardiac, pulmonary, digestive, haematological, neurological, locomotor or psychiatric disease, which in the opinion of the Investigator would compromise the safety of the subject;	4.
		History of asthma requiring regular medication.	5.
		Known sensitivity to the test article, similar materials or their constituents.	6.
		Current participation in a clinical trial or follow-up.	7.
No	Yes	phibitions and Restrictions	Pro
		Subjects agree to use the trial product assigned as instructed, instead of their usual brand for the duration of the study.	1.

Final v2 Page **17** of **30**

<u>APPENDIX 3 – CONTINUED</u>

Have you ever had any skin problems related to the use of any of the following types of material?

Material	Yes		No	When? – Which products? – What happens?
Nutritional				
Supplements				
Other				
Personal Care				
Products –				
please specify				

Questionnaire checked and co	nfirmed by:	
Signature	 Date	

Final v2 Page **18** of **30**

APPENDIX 4: TEST ARTICLES INCI LISTINGS

Active Supplement

Ingredients:

350 mg total of Redicalm proprietary blend: L-Theanine, Ashwagandha Powder, Lemon Balm Powder, Passion Flower Powder, 5 HTP.

Other ingredients: Vegetable capsule (capsule shell), Rice Flour, Magnesium Stearate.

<u>Placebo Supplement</u>

Ingredients:

Gelatin capsule (capsule shell).

Final v2 Page **19** of **30**

APPENDIX 5: RANDOMISATION

S. KANDOMISATI			
SUBJECT NUMBER	PRODUCT	SUBJECT NUMBER	PRODUCT
1	A	27	В
2	A	28	В
3	A	29	А
4	A	30	А
5	В	31	В
6	A	32	В
7	A	33	В
8	В	34	A
9	В	35	В
10	В	36	A
11	A	37	В
12	В	38	А
13	A	39	В
14	В	40	В
15	В	41	А
16	A	42	А
17	A	43	В
18	В	44	В
19	В	45	А
20	A	46	А
21	В	47	А
22	A	48	А
23	В	49	А
24	В	50	А
25	В	51	А
26	В	52	В

Final v2 Page **20** of **30**

APPENDIX 6: SUBJECT DIARY

Please take the test product supplied to you as instructed, **2 CAPSULES ONCE A DAY**.

Please answer the 2 questions in the table every day, following the answer key below.

If you have any problems with the product please call the office at 01245 934050 during business hours, 9:00am to 5:00pm.

PLEASE USE BLACK INK

Day	Date	Did you take 2 ☑ Chec		If NO, explain why	Q1 - After taking this product I noticed an improvement in my level of anxiety.	Q2 - After taking this product I felt calmer after only 30 minutes
1		☐ Yes	□ No			
2		☐ Yes	□ No			
3		☐ Yes	□ No			
4		☐ Yes	□ No			
5		☐ Yes	□ No			
6		☐ Yes	□ No			
7		☐ Yes	□ No			
8		☐ Yes	□ No			
9		☐ Yes	□ No			
10		☐ Yes	□ No			
11		☐ Yes	□ No			
12		☐ Yes	□ No			
13		☐ Yes	□ No			
14		☐ Yes	□ No			
15		☐ Yes	□ No			
16		☐ Yes	□ No			
17		☐ Yes	□ No			
18		☐ Yes	□ No			
19		☐ Yes	□ No			
20		☐ Yes	□ No			
21		☐ Yes	□ No			
22		☐ Yes	□ No			
23		☐ Yes	□ No			
24		☐ Yes	□ No			
25		☐ Yes	□ No			
26		☐ Yes	□ No			
27		☐ Yes	□ No			
28		☐ Yes	□ No			
29		☐ Yes	□ No			
		☐ Yes	□ No			
30		Please bring bad	•			
		and da	nily.			

Final v2 Page **21** of **30**

Answer Key for the 2 questions:

Strongly Disagree = 1

Disagree = 2

Neither Agree or Disagree = 3

Agree = 4

Strongly Agree = 5

Comments:			
			,

Final v2 Page **22** of **30**

APPENDIX 7: SELF-PERCEPTION QUESTIONNAIRE

NUTUSE1M: Self-Perception Questionnaire (Post-Treatment)

Subject details

Initials	Age
Q1 After taking this product I noticed an	Q6 After taking this product I felt less worried.
improvement in my level of anxiety.	Strongly disagree
Strongly disagree	Disagree
Disagree	Neither agree nor disagree
Neither agree nor disagree	Agree
Agree	Strongly agree
Strongly agree	
Q2 After taking this product I felt calmer after only 30 minutes.	Q7 After taking this product I felt I had better concentration
Strongly disagree	Strongly disagree
Disagree	Disagree
Neither agree nor disagree	Neither agree nor disagree
Agree	Agree
Strongly agree	Strongly agree
Q3 After taking this product I felt calmer.	Q8 After taking this product, my breathing was
Strongly disagree	more relaxed
Disagree	Strongly disagree
Neither agree nor disagree	Disagree
Agree	Neither agree nor disagree
Strongly agree	Agree.
	Strongly agree
Q4 After taking this product I was able to sleep better.	Q9 After taking this product I had a more restful
Strongly disagree	sleep
Disagree	Strongly disagree
Neither agree nor disagree	Disagree
Agree	Neither agree nor disagree
Strongly agree	Agree
	Strongly agree
Q5 After taking this product I felt more relaxed.	Q10. After taking this product I felt I had more energy
Strongly disagree.	Strongly disagree
Disagree.	Disagree
Neither agree nor disagree	Neither agree nor disagree
Agree.	Agree
Strongly agree	Strongly agree

Final v2 Page **23** of **30**

Self-Perception Questionnaire - Continued

Q11 After taking the product I felt more alert during the day	Q17 My usual supplement for my anxiety is:
Strongly disagree	
Disagree	
Neither agree nor disagree	
Agree	
Strongly agree	
shorighy agree	Q18 I would recommend this product to a friend or
Q12 After taking the product I felt I was able to face	family member.
my normal anxiety triggers	Strongly disagree
Strongly disagree	Disagree
Disagree	Neither agree nor disagree
Neither agree nor disagree	Agree
Agree	Strongly agree
Strongly agree	on on gry alg. sommer
onorigiy agroo	
Q13 After taking the product I felt more at ease with my daily routine	Q19 Is there anything about this product you like?
Strongly disagree	
Disagree	
Neither agree nor disagree	
Agree	
Strongly agree	
Q14 After taking the product I felt less irritable	Q20 Is there anything about this product you dislike?
Strongly disagree	
Disagree	
Neither agree nor disagree	
Agree	
Strongly agree	
Q15 The supplement was easy to include in my daily routine	
Strongly disagree	
Disagree	
Neither agree nor disagree	
Agree	
Strongly agree	
Q16 The supplement was easy to swallow	
Strongly disagree	
Disagree	
Neither agree nor disagree \square	
Agree	
Strongly agree	

Final v2 Page **24** of **30**

PCR CORP REPORT: NUTUSE1M 13th December 2016

<u>APPENDIX 8: SELF-PERCEPTION QUESTIONNAIRE INDIVIDUAL RESPONSES – TEST SUPPLEMENT</u>

Responses Key: 1=Strongly disagree; 2=Disagree; 3=Neither agree nor disagree; 4=Agree; 5=Strongly agree

11000011000	itoy: i onei	<u> 1917</u>	01	Q2	Q3	Q4	Q5	Q6
			After taking this product I	After taking this product I				
			noticed an improvement in my	felt calmer after only 30	After taking this product I			
Product Code	Subject number	Age	level of anxiety	minutes	felt calmer	was able to sleep better	felt more relaxed	felt less worried
Α	1	46	4	4	5	4	4	4
Α	2	50	4	4	4	4	4	4
Α	3	32	4	4	5	4	5	5
Α	4	29	4	4	4	4	4	4
Α	6	47	4	3	4	4	4	4
Α	7	35	4	4	4	4	4	3
Α	11	53	5	3	5	4	4	5
Α	13	28	4	4	4	4	4	4
Α	16	41	5	4	4	3	4	4
Α	17	28	5	3	4	4	5	4
Α	20	37	4	4	4	4	4	3
Α	22	36	4	3	5	4	4	4
Α	29	34	4	4	4	4	4	4
Α	30	49	4	3	4	4	5	3
Α	34	18	4	4	5	4	4	3
Α	36	46	5	4	5	4	4	4
Α	38	26	4	4	4	4	5	4
Α	41	62	4	5	4	4	5	4
Α	42	41	5	4	5	5	5	5
Α	45	32	4	4	4	4	4	4
Α	46	36	4	2	4	4	4	3
Α	47	31	5	3	4	5	5	4
A	48	53	5	4	4	4	4	4
A	49	25	4	3	3	4	3	4
A	50	36	4	5	4	4	4	4
	ly Agree		28.00%	8.00%	28.00%	8.00%	28.00%	12.00%
	gree		72.00%	60.00%	68.00%	88.00%	68.00%	68.00%
	gree Nor Disagree		0.00%	28.00%	4.00%	4.00%	4.00%	20.00%
	Disagree		0.00%	4.00%	0.00%	0.00%	0.00%	0.00%
	gly Disagree		0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Top 2	2 Responses		100.00%	68.00%	96.00%	96.00%	96.00%	80.00%

Final v2 Page **25** of **30**

PCR CORP REPORT: NUTUSE1M 13th December 2016

APPENDIX 8 - CONTINUED

ALLENDIA O	TTITITOED						
Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14
After taking this product I						After taking this product I felt	
felt I had better	After taking this product, my					more at ease with my daily	After taking the product I
concentration	breathing was more relaxed	had a more restful sleep	felt I had more energy	day	normal anxiety triggers	routine	felt less irritable
4	4	3	4	5	4	4	4
4	4	4	4	4	4	4	4
5	4	4	4	4	4	5	4
4	4	4	4	4	4	4	4
4	4	4	4	5	4	4	4
4	4	4	4	4	4	4	4
4	4	4	5	5	4	5	5
5	4	4	5	4	4	4	4
4	3	3	4	5	4	5	4
4	5	4	4	4	3	4	5
4	3	4	4	4	2	4	4
4	4	4	5	4	5	5	4
4	5	5	4	4	4	4	4
4	4	5	5	4	4	4	4
4	4	4	4	4	3	4	4
5	4	4	4	4	4	5	5
4	4	4	4	4	4	4	4
4	3	4	5	4	4	4	5
5	4	5	5	5	4	4	5
4	4	4	4	4	4	4	4
4	4	4	4	4	4	4	3
5	5	4	5	5	5	5	5
4	5	4	4	4	4	4	5
4	2	4	3	4	3	4	4
5	4	4	5	4	4	4	4
24.00%	16.00%	12.00%	32.00%	24.00%	8.00%	24.00%	28.00%
76.00%	68.00%	80.00%	64.00%	76.00%	76.00%	76.00%	68.00%
0.00%	12.00%	8.00%	4.00%	0.00%	12.00%	0.00%	4.00%
0.00%	4.00%	0.00%	0.00%	0.00%	4.00%	0.00%	0.00%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
100.00%	84.00%	92.00%	96.00%	100.00%	84.00%	100.00%	96.00%

Final v2 Page 26 of 30

13th December 2016

PCR CORP REPORT: NUTUSE1M

Q15 The supplement was	Q16	Q17	Q18 I would recommend this	Q19	Q20
	The supplement was easy	My usual supplement for my anxiety	product to a friend or	Is there anything about this	Is there anything about this
daily routine	to swallow	is:	family member	product you like?	product you dislike?
5	4	Kalms	4		
4	4	Wellman	4		
5	4		5	really good would recommend	
4	4	Multi Vitimans	4	Good product	
5	4		4	Enjoyed using it	
4	4	Holland & Barrett	4		
5	4	Kalms	5	Brilliant Product	
4	4		5	Really good	
5	4		5	Would buy this	
4	5		4		
4	4	Holland & Barrett	5	Worked a treat	
5	5	Natures Way	5		
4	4		4		
4	4	Day and Night	5		
5	5	Boots Supplements	5	Gave me a boost	
5	5	Holland & Barrett	5	Fantastic	
4	4	Nutra plus	4	Really good	
5	5	Anxiety Ease	5	Really good	
5	5	Herbal Plus	5	Brilliant	
4	4		4		
4	5	Vitabiotics	5	Would purchase really good	
5	5		5	Fantastic supplement	
5	5	natural supplements	5	Worked Well Brilliant Product	
4	4	Local Herbalist	4	Easy to swallow	Taste
4	4		4		
48.00%	36.00%		56.00%		
52.00%	64.00%		44.00%		
0.00%	0.00%		0.00%		
0.00%	0.00%		0.00%		
0.00%	0.00%		0.00%		
100.00%	100.00%		100.00%		

Final v2 Page **27** of **30**

PCR CORP REPORT: NUTUSE1M 13th December 2016

APPENDIX 9: SELF-PERCEPTION QUESTIONNAIRE INDIVIDUAL - PLACEBO

			Q1	Q2	Q3	Q4	Q5	Q6
			After taking this product I	After taking this product I				
			noticed an improvement in my	felt calmer after only 30	After taking this product I		After taking this product I	
Product Code	Subject number	Age	level of anxiety	minutes	felt calmer	was able to sleep better	felt more relaxed	felt less worried
В	5	19	4	3	4	2	4	3
В	8	37	4	2	4	3	4	3
В	9	23	3	3	4	3	4	3
В	10	46	4	4	4	4	4	4
В	12	42	4	4	4	2	3	3
В	14	31	4	4	4	4	3	3
В	15	35	4	3	4	3	4	3
В	18	30	3	3	3	2	3	3
В	19	26	4	4	4	4	4	2
В	21	49	3	2	4	2	4	4
В	23	43	4	4	4	4	4	4
В	24	45	4	2	4	2	3	3
В	25	38	4	4	4	4	4	3
В	26	46	3	3	3	3	3	2
В	27	29	4	4	4	4	4	4
В	28	21	4	4	4	3	3	4
В	31	31	4	2	3	4	4	2
В	32	48	4	4	4	2	4	3
В	33	52	4	3	4	4	4	4
В	35	24	4	4	4	3	4	4
В	37	19	4	4	4	4	4	4
В	39	59	2	2	2	2	2	2
В	40	24	4	4	4	4	4	4
В	43	23	4	3	3	4	4	4
В	44	40	3	2	3	2	2	2
Strong	gly Agree		0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
A	gree		76.00%	48.00%	76.00%	44.00%	68.00%	40.00%
Neither A	gree Nor Disagree		20.00%	28.00%	20.00%	24.00%	24.00%	40.00%
	Disagree		4.00%	24.00%	4.00%	32.00%	8.00%	20.00%
Stror	ngly Disagree		0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Top	2 Responses		76.00%	48.00%	76.00%	44.00%	68.00%	40.00%

Final v2 Page **28** of **30**

PCR CORP REPORT: NUTUSE1M 13th December 2016

APPENDIX 9 - CONTINUED

Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14
After taking this product I				After taking this product I		After taking this product I felt	
felt I had better	After taking this product, my			felt more alert during the	felt I was able to face my	more at ease with my daily	After taking the product I
concentration	breathing was more relaxed	had a more restful sleep	felt I had more energy	day	normal anxiety triggers	routine	felt less irritable
4	4	3	4	3	3	4	4
4	3	2	3	4	3	3	4
3	3	3	3	3	3	3	4
4	4	4	4	4	4	4	4
4	3	2	4	4	3	3	4
4	3	4	4	4	2	4	3
3	4	3	3	4	3	4	4
3	2	3	3	3	3	4	3
4	3	4	4	4	4	4	4
3	3	1	3	3	2	3	3
4	4	4	4	4	4	4	4
4	3	4	3	3	4	4	3
4	4	4	4	4	3	4	3
3	3	3	3	3	3	3	2
4	4	4	4	4	4	4	4
3	3	3	4	4	4	3	4
3	3	4	4	3	3	4	3
3	3	3	4	3	3	4	3
3	3	4	4	4	3	4	4
4	3	3	4	4	4	4	5
4	2	4	4	4	4	3	3
2	2	2	2	2	2	2	3
4	2	3	4	4	2	3	3
4	3	4	4	3	3	4	3
2	3	3	2	3	2	2	3
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.00%
56.00%	24.00%	44.00%	64.00%	56.00%	32.00%	60.00%	44.00%
36.00%	60.00%	40.00%	28.00%	40.00%	48.00%	32.00%	48.00%
8.00%	16.00%	12.00%	8.00%	4.00%	20.00%	8.00%	4.00%
0.00%	0.00%	4.00%	0.00%	0.00%	0.00%	0.00%	0.00%
56.00%	24.00%	44.00%	64.00%	56.00%	32.00%	60.00%	48.00%

Final v2 Page **29** of **30**

13th December 2016

PCR CORP REPORT: NUTUSE1M

Q15	Q16	Q17	Q18	Q19	Q20
The supplement was			I would recommend this		
		My usual supplement for my anxiety	product to a friend or	Is there anything about this	Is there anything about this
daily routine	to swallow	is:	family member	product you like?	product you dislike?
5	5		4		
5	4		4	Easy to swallow	
4	4	natural care	3		Didn't feel much difference
4	4		4	Liked it	
5	4	Multi Vitimans	3	was ok	
4	3		4	Easy to swallow	Were bland
4	4		4		
4	4	Herbs & Vitimans	3		I Prefer What I Use
4	4	Herbal Plus	5		
4	4	Natures	4		
4	4	Holistic Herbs	4		
5	4	Kalms	4		
4	5	Holland & Barrett	5	Thought they were good	
4	4	Optima	2		Did not do anything for me
4	4	Pure Natural	4		
4	2	Vitabiotics	4		
4	5	Kalms	4		
4	4		3		
4	3	Multi Vitimans	4		
5	4	Vitamins from various supermarkets	4		
4	4		4		
4	3	Pure	2		
4	4	Holland & Barrett	3	was easy to swallow	
4	4		4		
4	3	Kalms	2		No affect on me
20.00%	12.00%		8.00%		
80.00%	68.00%		60.00%		
0.00%	16.00%		20.00%		
0.00%	4.00%		12.00%		
0.00%	0.00%		0.00%		
100.00%	80.00%		68.00%		
Final v2					Daga 20 of 20

Final v2